Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CDA | P32320 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445177 | 1.00 | LMNA (0.60) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL1665233 | 1.00 | LMNA (0.60) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL16805407 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL156037 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL18858919 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL9856439 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL9856409 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL156036 | 0.91 | LMNA (0.62) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL6829082 | 0.90 | LMNA (0.58) | LMNAMTORALDH1A1TP53DNMT1 | |
| SCHEMBL6418055 | 0.90 | LMNA (0.60) | LMNAMTORALDH1A1TP53DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| EP-3670523-B1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND THEIR USE IN METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
| US-11001886-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | AGILENT TECHNOLOGIES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3670523-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Agilent Technologies, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2755984-B1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190127790-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2019-05-02 | — | — | US | disclosed |
| US-10041115-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | LASERGEN, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2307565-B1 | REVERSIBLE NUCLEOSIDES AND NUCLEOTIDES TERMINATORS AND THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170327886-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2755984-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Lasergen, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2013040257-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | DNMT1, DNMT3A, DNMT3B | LMNA 2673/4885MTOR 840/4885ALDH1A1 669/4885 |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | LMNA 357/4885MTOR 4784/4885ALDH1A1 1889/4885 |
| US-20190127790-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | LMNA 275/4885MTOR 4849/4885ALDH1A1 2244/4885 |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | DNMT1, DNMT3B, DNMT3A | LMNA 2458/4885MTOR 601/4885ALDH1A1 466/4885 |
| US-10041115-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | RNGTT, NT5C3B, NSUN2 | LMNA 275/4885MTOR 4845/4885ALDH1A1 2163/4885 |
| US-11001886-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | RNGTT, NT5C3B, NSUN2 | LMNA 275/4885MTOR 4845/4885ALDH1A1 2163/4885 |
| US-20170327886-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | LMNA 275/4885MTOR 4849/4885ALDH1A1 2244/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | LMNA 357/4885MTOR 4784/4885ALDH1A1 1889/4885 |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | LMNA 275/4885MTOR 4849/4885ALDH1A1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.